INTRODUCTION {#S1}
============

Two landmark trials, the Diabetes Control and Complications Trial (DCCT) and the United Kingdom Prospective Diabetes Study (UKPDS), emphasize the significance of glycemic control in patients with diabetes mellitus.[@B1],[@B2],[@B3] These studies reported that maintaining glycemic control (i.e., hemoglobin A1C \[A1C\]\<7.0%) is necessary to reduce the risk of microvascular and macrovascular complications, including nephropathy, neuropathy, retinopathy, and cardiovascular events, such as myocardial infarction or stroke.[@B1],[@B2],[@B3] An epidemiological review of the UKPDS revealed that a reduction in A1C of 1 percentage point resulted in a 35% reduction in the microvascular complications (i.e., retinopathy, nephropathy, and neuropathy) of diabetes mellitus type 2 (DM 2).[@B1],[@B2] Based largely on the results of these two trials, the American Diabetes Association recommends a target A1C goal of \<7% for most patients with diabetes and maintains that glycemic control is fundamental to reducing the microvascular complications of the disease.[@B4] In fact, a recent hyperglycemia management consensus algorithm advocates that an A1C≥7 serves as a call to action to optimize therapy.[@B5]

Thiazolidinedione (TZD) agents, selective agonist of the peroxisome proliferator-activated receptor-gamma subtype (PPARY), are oral antihyperglycemic agents approved by the Food and Drug Administration (FDA) for use in DM2 as monotherapy or in combination with sulfonylureas, metformin, or insulin.[@B6],[@B7] While TZDs have demonstrated efficacy in the reduction of A1C values when used in combination with other oral antihyperglycemic agents in clinical trials,[@B8],[@B9],[@B10],[@B11] limited real-world effectiveness data are available.[@B12],[@B12],[@B13],[@B14],[@B15],[@B16],[@B16] In addition, few studies have reported on factors associated with change in A1C in clinical practice.[@B12],[@B13],[@B17],[@B18] Importantly, knowledge of characteristics of patients who respond to adjunct pioglitazone is narrow. The intent of this study was to evaluate pre-to-post the effectiveness of adjunctive pioglitazone therapy in patients with DM2 and provide additional data regarding the patient characteristics associated with changes in A1C after the addition of pioglitazone to existing oral antihyperglycemic therapy in a diverse, real-world population of patients managed in routine clinical practice.

METHODS {#S2}
=======

Setting and Design {#S3}
------------------

This was a naturalistic, retrospective, pre-to-post analysis conducted at Kaiser Permanente Colorado, a group model, not-for-profit, health maintenance organization with approximately 450,000 members in the Denver/Boulder metropolitan area, operating 18 regional medical offices. All phases of the study were approved by the Kaiser Permanente Colorado Institutional Review Board.

Patient Population {#S4}
------------------

Active Kaiser Permanente Colorado patients 18 years of age and older who had newly initiated pioglitazone therapy to existing other oral antihyperglycemic medication therapy between January 1, 2002 and December 31, 2005 were eligible for inclusion ([Figure 1](#F1){ref-type="fig"}). A newly-initiated regimen was identified as a pioglitazone prescription purchased from a Kaiser Permanente Colorado pharmacy during the study period with no other pioglitazone prescription purchased in the prior 180 days (to ensure that 90- and 180-day supply mail order prescription purchases were accounted for in this assessment). The first purchase date of the newly-initiated pioglitazone therapy was set as the study index date. Patients were included if they had continuous coverage for a Kaiser Permanente Colorado pharmacy benefit for the 180 days prior to the index date (to ensure comprehensive prescription purchase history) and remained on a single dose of pioglitazone for at least 90 days after initiation of therapy. The study stable date was defined as the date when a patient had remained on a single dose of pioglitazone for 90 days. In addition, patients that had purchased insulin therapy at any time in the 180 days prior to the index date and 180 days after the stable date were excluded.

![Study Timeline](pharmpract-06-079-g001){#F1}

Data Collection {#S5}
---------------

Data were extracted from integrated electronic medical, pharmacy, and laboratory record databases. Patients' data were linked across databases by their Kaiser Permanente Colorado unique nine digit health record number. Validity of these data sources has been described previously.[@B19] Pharmacy records were queried using Generic Product Identifier numbers[@B20] to assess medication prescription purchases and purchase dates during the 180 days prior to the index date (these data were required to assess inclusion criteria and calculate a chronic disease score[@B21]). Patient demographics were extracted from their pharmacy records. Medical records were queried with International Classification of Diseases, Ninth Revision (ICD-9) codes to identify a medical office diagnosis for coronary artery disease, chronic kidney disease, gastroparesis, previous myocardial infarction, neuropathy, retinopathy, and/or previous stroke in the 180 days prior to the index date. Age was calculated as of the index date. The strength of the dose of pioglitazone at the stable date was recorded (stable dose). Electronic laboratory records data were queried to identify the most proximal A1C in the 90 days prior to the index date for the baseline measurement and between 90 and 180 days after the stable date for the follow-up measurement ([Figure 1](#F1){ref-type="fig"}). Patients without both a baseline and follow-up A1C measurement were excluded. Baseline weight was identified from integrated medical records; however, as data were missing in 22% of the included patients, analysis was not undertaken.

Outcomes {#S6}
--------

The primary outcome was to quantify from baseline to follow-up the absolute change in A1C values after initiation of pioglitazone. Secondary analyses were performed to quantify the proportions of patients achieving a ≥1 percentage point decrease in A1C and an A1C\<7% during the follow-up. Additionally, factors (predictors) independently associated with absolute A1C change, achieving a ≥1 percentage point decrease in A1C, and achieving an A1C\<7% were identified.

Analysis {#S7}
--------

Time (in days) between index date and follow-up A1C measurement was calculated. A chronic disease score,[@B21],[@B22] a risk adjustor for baseline health status, was calculated for all patients using pharmacy purchase data for the 180 days prior to the index date. Chronic disease scores can range from 0 to 35 with increasing scores indicating an increasing count of chronic diseases under treatment. Use of the chronic disease score allows for the accounting of each patient's chronic disease burden at the time of his/her initiation of pioglitazone. Persistence with oral antihyperglycemic agents at the time of the follow-up A1C was determined based on the medication sold date, days supplied, and quantity dispensed resulting in a day's supply of medication within +/- two weeks of the follow-up A1C measurement date.

Baseline patient characteristics and study outcomes were reported as means and standard deviations for interval- and ratio-level variables (e.g., age, time) and proportions for nominal- and ordinal-level data (e.g., gender, use of other oral antihyperglycemic medications). Interval- and ratio-level variables were assessed for the normality of their distributions. Times were log transformed to normalize their distribution. The paired-sample t-test[@B23] was used to evaluate the change from baseline in A1C. Independent sample t-tests and chi-square tests of association[@B23] were used to compare means and proportions between sub-groups (i.e., those that did and did not achieve a 1 percentage point decrease in A1C and a \<7% A1C). To identify predictors of change in A1C, multivariate linear and logistic regression modeling[@B23] were utilized. Age, gender, daily stable pioglitazone dose (15 mg, 30 mg, and 45 mg), time between index date and follow-up A1C measurements, baseline metformin, glipizide, glyburide, antihyperlipidemic and antihypertensive medications use, chronic disease score, persistence with pioglitazone, retinopathy and neuropathy diagnoses, and baseline A1C measurement were entered into all models. Diagnoses for coronary artery disease, chronic kidney disease, gastroparesis, and previous myocardial infarction, stroke and baseline sulfonylurea use were not entered in the models due to their very low and high prevalence rates, respectively. The baseline A1C values were assessed as a continuous and categorized (i.e., ≤8% vs. \>8%) variable.

RESULTS {#S8}
=======

In total, 128 patients were included in the analysis ([Figure 2](#F2){ref-type="fig"}). The mean age was 65 years, 38% were female, 41% were receiving a stable dose of 15 mg pioglitazone, mean A1C was 8.4%, 74% had an A1C\>8% at the time of pioglitazone initiation, and mean chronic disease score was 7 (indicating, on average, a clinically significant chronic disease burden[@B21]) ([Table 1](#T1){ref-type="table"}). The mean absolute A1C reduction was 1.2 percentage points (interquartile range= -0.4, -2.1 percentage points, p\<0.001), 59% achieved a ≥1 percentage point decrease in A1C, and 44% achieved an A1C\<7%.
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###### 

Baseline Patient Characteristics Overall and by A1C Decrease[\*](#t1fn1){ref-type="fn"} Cohort

  ------------------------------------------------------------ ------------------ ----------------------------------------------- ------------------------------------------------ ----------------------------------- -------
  Characteristic                                               Overall (n=128)    Achieved ≥1 Percentage Decrease in A1C (n=75)   Achieved \<1 Percentage Decrease in A1C (n=53)   P-Value[1](#t1fn2){ref-type="fn"}   
  Mean Age[2](#t1fn2){ref-type="fn"} in Years (SD)             64.6 (10.5)        64.5 (10.6)                                     64.8 (10.4)                                      0.905                               
  Female (%)                                                   37.5               37.3                                            37.7                                             0.963                               
  Mean Baseline A1C %[2](#t1fn2){ref-type="fn"} (SD)           8.4 (1.0)          8.9 (0.9)                                       7.7 (0.7)                                        \<0.001                             
  Baseline A1C≤8.0%[2](#t1fn2){ref-type="fn"} (%)              35.9               14.7                                            66.0                                             \<0.001                             
  Mean Weight in Kilograms[2](#t1fn2){ref-type="fn"} (n, SD)   91.0 (100, 18.3)   93.1 (59, 18.3)                                 87.9 (41, 19.3)                                  0.169                               
  Metformin Use[3](#t1fn2){ref-type="fn"} (%)                  74.2               70.7                                            79.3                                             0.274                               
  Glipizide Use[3](#t1fn2){ref-type="fn"} (%)                  37.5               42.7                                            30.2                                             0.151                               
  Glyburide Use[3](#t1fn2){ref-type="fn"} (%)                  57.8               50.7                                            67.9                                             0.052                               
  Sulfonylurea Use[3](#t1fn2){ref-type="fn"} (%)               96.1               94.7                                            98.1                                             0.325                               
  Stable Pioglitazone Daily Dose (%)                                                                                                                                                                                   
     15 mg                                                     41.4               42.7                                            39.6                                             0.731                               
     30 mg                                                     35.9               40.0                                            30.2                                             0.255                               
     ≥45 mg                                                    22.7               17.3                                            30.2                                             0.087                               
  Persistent with Pioglitazone[4](#t1fn2){ref-type="fn"}       (%)                80.5                                            80.0                                             81.1                                0.874
  Related Medication Use[3](#t1fn2){ref-type="fn"} (%)                                                                                                                                                                 
     ACE Inhibitor                                             69.5               65.3                                            75.5                                             0.220                               
     Beta Blocker                                              38.3               44.0                                            30.2                                             0.113                               
     Calcium Channel Blocker                                   18.0               18.7                                            17.0                                             0.807                               
     Thiazide                                                  32.0               34.7                                            28.3                                             0.447                               
     Statin Antihyperlipidemic                                 74.2               73.3                                            75.5                                             0.785                               
     Non-Statin Antihyperlipidemic                             25.8               32.0                                            17.0                                             0.056                               
  Mean Chronic Disease Score (SD)                              7.0 (2.6)          7.1 (2.9)                                       6.9 (2.1)                                        0.757                               
  Comorbidity[5](#t1fn2){ref-type="fn"} (%)                                                                                                                                                                            
     Coronary Artery Disease                                   3.9                1.3                                             7.6                                              0.074                               
     Chronic Kidney Disease                                    4.6                2.7                                             0.0                                              0.231                               
     Gastroparesis                                             0.0                0.0                                             0.0                                              1.000                               
     Previous Myocardial Infarction                            0.0                0.0                                             0.0                                              1.000                               
     Neuropathy                                                7.0                5.3                                             9.4                                              0.371                               
     Retinopathy                                               5.5                2.7                                             9.4                                              0.097                               
     Previous Stroke                                           0.8                1.3                                             0.0                                              0.399                               
  ------------------------------------------------------------ ------------------ ----------------------------------------------- ------------------------------------------------ ----------------------------------- -------

Achievement occurred during 90 to 180 days after date of initiation of stable dose

1 -- Between cohorts

2 -- At time of pioglitazone initiation

3 -- As assessed by a purchase for the medication in the 90 days prior to pioglitazone initiation

4 -- At the time of the follow-up A1C measurement

5 -- As assessed by a medical office diagnosis for the indication in the 180 days prior to pioglitazone initiation

In bivariate analysis, patients who achieved a ≥1 percentage point decrease in A1C had a higher mean baseline A1C (p\<0.001) and were less likely to have had a baseline A1C ≤8% (p\<0.001) than patients who did not achieve a ≥1 percentage point decrease in A1C. All patients were persistent with their baseline metformin, glyburide, glipizide, and/or sulfonylurea antihyperglycemic prescription medications at the time of their follow-up A1C measurement (p\>0.05, data not shown). There were no other differences in clinical and demographic characteristics (p\>0.05) between the groups of patients who were or were not able to achieve an A1C\<7%.

Multivariate linear regression analysis revealed two predictors of absolute change in A1C: baseline A1C level (beta-coefficient= -0.831; p\<0.001) and time between the index date and follow-up A1C measurement date (beta-coefficient=0.528; p=0.003) (adjusted R^2^=0.55) ([Table 2](#T2){ref-type="table"}). The beta-coefficients indicate that when comparing two patients with all other characteristics being equal, the patient with the higher baseline A1C will have a more favorable response to pioglitazone. Conversely, the patient with a greater number of days between the index date and follow-up A1C measurement date will have a less favorable response to pioglitazone. When categorizing baseline A1C at ≤8% and ≤8%, patients with an A1C≤8% (beta-coefficient=1.220; p\<0.001) were predicted to have a less favorable response to pioglitazone, also (adjusted R^2^=0.28).

###### 

Predictors of Absolute Change in A1C

  --------------------------------------------------------------- --------------------------------------------------- ---------------------------------------------------- --------------- ---------
                                                                  Continuous Baseline A1C[1](#t2fn1){ref-type="fn"}   Categorical Baseline A1C[2](#t2fn1){ref-type="fn"}                   
  Potential Predictor                                             β-Coefficient                                       P-Value                                              β-Coefficient   P-Value
  Baseline A1C                                                    -0.831                                              \<0.001                                              \_\_            \_\_
     ≤ 8%                                                         \_\_                                                \_\_                                                 1.220           \<0.001
     \> 8%                                                        \_\_                                                \_\_                                                 \_\_            \_\_
  Age                                                             -0.000                                              0.979                                                0.002           0.847
  Gender                                                                                                                                                                                   
     Female                                                       -0.069                                              0.676                                                -0.094          0.655
     Male                                                         \_\_                                                \_\_                                                 \_\_            \_\_
  Log of Days between Index Date and Follow-Up A1C Measurements   0.528                                               0.026                                                0.573           0.010
  Metformin Use                                                                                                                                                                            
     Yes                                                          0.030                                               0.874                                                0.256           0.287
     No                                                           \_\_                                                \_\_                                                 \_\_            \_\_
  Glipizide Use                                                                                                                                                                            
     Yes                                                          0.224                                               0.382                                                0.041           0.900
     No                                                           \_\_                                                \_\_                                                 \_\_            \_\_
  Glyburide Use                                                                                                                                                                            
     Yes                                                          0.209                                               0.395                                                0.081           0.795
     No                                                           \_\_                                                \_\_                                                 \_\_            \_\_
  Stable Pioglitazone Daily Dose                                                                                                                                                           
     15 mg                                                        0.225                                               0.391                                                0.382           0.254
     30 mg                                                        -0.172                                              0.425                                                -0.085          0.759
     ≥45 mg                                                       \_\_                                                \_\_                                                 \_\_            \_\_
  Persistent with Pioglitazone                                                                                                                                                             
     Yes                                                          -0.101                                              0.603                                                -0.243          0.329
     No                                                           \_\_                                                \_\_                                                 \_\_            \_\_
  ACE Inhibitor Use                                                                                                                                                                        
     Yes                                                          0.133                                               0.537                                                0.015           0.955
     No                                                           \_\_                                                \_\_                                                 \_\_            \_\_
  Beta Blocker Use                                                                                                                                                                         
     Yes                                                          -0.002                                              0.992                                                -0.056          0.791
     No                                                           \_\_                                                \_\_                                                 \_\_            \_\_
  Calcium Channel Blocker Use                                                                                                                                                              
     Yes                                                          0.104                                               0.573                                                -0.043          0.854
     No                                                           \_\_                                                \_\_                                                 \_\_            \_\_
  Thiazide Use                                                                                                                                                                             
     Yes                                                          0.089                                               0.575                                                0.227           0.258
     No                                                           \_\_                                                \_\_                                                 \_\_            \_\_
  Statin Antihyperlipidemic Use                                                                                                                                                            
     Yes                                                          0.173                                               0.358                                                0.195           0.417
     No                                                           \_\_                                                \_\_                                                 \_\_            \_\_
  Non-Statin Antihyperlipidemic Use                                                                                                                                                        
     Yes                                                          -0.353                                              0.055                                                -0.339          0.147
     No                                                           \_\_                                                \_\_                                                 \_\_            \_\_
  Chronic Disease Score                                           -0.057                                              0.111                                                -0.036          0.426
  Neuropathy                                                                                                                                                                               
     Yes                                                          -0.186                                              0.548                                                -0.105          0.791
     No                                                           \_\_                                                \_\_                                                 \_\_            \_\_
  Retinopathy                                                                                                                                                                              
     Yes                                                          -0.138                                              0.697                                                0.115           0.797
     No                                                           \_\_                                                \_\_                                                 \_\_            \_\_
  --------------------------------------------------------------- --------------------------------------------------- ---------------------------------------------------- --------------- ---------

1 -- Adjusted R-Square = 0.55

2 -- Adjusted R-Square = 0.28

Multivariate logistic regression analysis revealed two predictors of achieving a ≥1 percentage point decrease in A1C: baseline A1C level (odds ratio \[OR\]=12.84; p\<0.001) and time between the index date and follow-up A1C measurement date (OR=0.19; p=0.032) (c-statistic=0.92) ([Table 3](#T3){ref-type="table"}). When categorizing baseline A1C at ≤8% and ≤8%, patients with an A1C ≤8% (OR=0.04; p\<0.001) were predicted to be less likely to achieve a ≥1 percentage point decrease in A1C (c-statistic=0.88). These odds ratios support the previous model whereby patients with higher baseline A1Cs and longer times between initiation of pioglitazone and follow-up A1C measurements had more and less favorable, respectively, response to pioglitazone.

###### 

Predictors of Achieving a ≥1 Percentage Point Decrease in A1C

  --------------------------------------------------------------- --------------------------------------------------- ---------------------------------------------------- ------------ -------------
                                                                  Continuous Baseline A1C[1](#t3fn1){ref-type="fn"}   Categorical Baseline A1C[2](#t3fn1){ref-type="fn"}                
  Potential Predictor                                             Odds Ratio                                          95% CI                                               Odds Ratio   95% CI
  Baseline A1C                                                    12.84                                               4.53, 36.40                                          \_\_         \_\_
     ≤ 8%                                                         \_\_                                                \_\_                                                 0.04         0.01, 0.14
     \> 8%                                                        \_\_                                                \_\_                                                 \_\_         \_\_
  Age                                                             0.99                                                0.94, 1.06                                           0.98         0.94, 1.04
  Gender                                                                                                                                                                                
     Female                                                       0.38                                                0.11, 1.36                                           0.68         0.23, 1.97
     Male                                                         \_\_                                                \_\_                                                 \_\_         \_\_
  Log of Days between Index Date and Follow-Up A1C Measurements   0.19                                                0.04, 0.87                                           0.29         0.09, 0.98
  Metformin Use                                                                                                                                                                         
     Yes                                                          2.21                                                0.48, 10.10                                          0.88         0.28, 2.80
     No                                                           \_\_                                                \_\_                                                 \_\_         \_\_
  Glipizide Use                                                                                                                                                                         
     Yes                                                          0.32                                                0.06, 1.69                                           0.39         0.08, 1.94
     No                                                           \_\_                                                \_\_                                                 \_\_         \_\_
  Glyburide Use                                                                                                                                                                         
     Yes                                                          0.28                                                0.06, 1.40                                           0.27         0.06, 1.23
      No                                                          \_\_                                                \_\_                                                 \_\_         \_\_
  Stable Pioglitazone Daily Dose                                                                                                                                                        
     15 mg                                                        0.32                                                0.04, 2.59                                           0.43         0.08, 2.37
     30 mg                                                        2.35                                                0.46, 11.88                                          2.19         0.54, 8.98
     ≥45 mg                                                       \_\_                                                \_\_                                                 \_\_         \_\_
  Persistent with Pioglitazone                                                                                                                                                          
     Yes                                                          0.52                                                0.12, 2.19                                           0.72         0.20, 2.57
     No                                                           \_\_                                                \_\_                                                 \_\_         \_\_
  ACE Inhibitor Use                                                                                                                                                                     
     Yes                                                          0.29                                                0.06, 1.44                                           0.32         0.08, 1.38
     No                                                           \_\_                                                \_\_                                                 \_\_         \_\_
  Beta Blocker Use                                                                                                                                                                      
     Yes                                                          1.84                                                0.51, 6.63                                           1.93         0.63, 5.91
     No                                                           \_\_                                                \_\_                                                 \_\_         \_\_
  Calcium Channel Blocker Use                                                                                                                                                           
     Yes                                                          1.03                                                0.24, 4.47                                           1.24         0.36, 4.30
     No                                                           \_\_                                                \_\_                                                 \_\_         \_\_
  Thiazide Use                                                                                                                                                                          
     Yes                                                          0.90                                                0.29, 2.77                                           0.99         0.36, 2.78
     Yes                                                          \_\_                                                \_\_                                                 \_\_         \_\_
  Statin Antihyperlipidemic Use                                                                                                                                                         
     Yes                                                          0.60                                                0.15, 2.38                                           0.82         0.26, 2.60
      No                                                          \_\_                                                \_\_                                                 \_\_         \_\_
  Non-Statin Antihyperlipidemic Use                                                                                                                                                     
     Yes                                                          5.15                                                0.98, 24.03                                          3.20         0.91, 11.28
      No                                                          \_\_                                                \_\_                                                 \_\_         \_\_
  Chronic Disease Score                                           1.24                                                0.95, 1.61                                           1.17         0.91, 1.50
  Neuropathy                                                                                                                                                                            
     Yes                                                          0.17                                                0.02, 1.62                                           0.18         0.03, 1.17
     No                                                           \_\_                                                \_\_                                                 \_\_         \_\_
  Retinopathy                                                                                                                                                                           
     Yes                                                          0.79                                                0.08, 8.24                                           0.50         0.05, 4.29
     No                                                           \_\_                                                \_\_                                                 \_\_         \_\_
  --------------------------------------------------------------- --------------------------------------------------- ---------------------------------------------------- ------------ -------------

1 -- c-statistic = 0.92; 2 -- c-statistic = 0.88.

CI -- Confidence Interval

Multivariate logistic analysis revealed two predictors of achieving an A1C\<7%: baseline A1C level (OR=0.64; p=0.038), and time between the index date and follow-up A1C measurement date (OR=0.14; p=0.002) (c-statistic=0.78) ([Table 4](#T4){ref-type="table"}). When categorizing baseline A1C at ≤8% and ≤8%, patients with an A1C ≤8% (OR=4.27; p\<0.001) were predicted to be more likely to achieve an A1C\<7% (c-statistic=0.80). In total, these models indicate that, while patients with higher baseline A1C levels achieve greater absolute decreases in A1C, these patients are less likely to reach an A1C goal of \<7%.

###### 

Predictors of Achieving an A1C\<7%

  -------------------------------------------------- --------------------------------------------------- ---------------------------------------------------- ------------ -------------
                                                     Continuous Baseline A1C[1](#t4fn1){ref-type="fn"}   Categorical Baseline A1C[2](#t4fn1){ref-type="fn"}                
  Potential Predictor                                Odds Ratio                                          95% CI                                               Odds Ratio   95% CI
  Baseline A1C                                       0.64                                                0.42, 0.98                                           \_\_         \_\_
     ≤ 8%                                            \_\_                                                \_\_                                                 4.27         1.63, 11.23
     \> 8%                                           \_\_                                                \_\_                                                 \_\_         \_\_
  Age                                                1.01                                                0.96, 1.05                                           1.01         0.96, 1.05
  Gender                                                                                                                                                                   
     Female                                          1.66                                                0.66, 4.19                                           1.81         0.69, 4.76
     Male                                            \_\_                                                \_\_                                                 \_\_         \_\_
  Log of Days between Index Date and Follow-Up A1C                                                                                                                         
  Measurements                                       0.14                                                0.04, 0.48                                           0.12         0.03, 0.43
  Metformin Use                                                                                                                                                            
     Yes                                             0.41                                                0.14, 2.00                                           0.44         0.15, 1.29
     No                                              \_\_                                                \_\_                                                 \_\_         \_\_
  Glipizide Use                                                                                                                                                            
     Yes                                             0.86                                                0.21, 3.48                                           0.85         0.20, 3.60
     No                                              \_\_                                                \_\_                                                 \_\_         \_\_
  Glyburide Use                                                                                                                                                            
     Yes                                             0.82                                                0.21, 3.16                                           0.79         0.20, 3.21
     No                                              \_\_                                                \_\_                                                 \_\_         \_\_
  Stable Pioglitazone Daily Dose                                                                                                                                           
     15 mg                                           0.44                                                0.10, 1.98                                           0.50         0.11, 2.37
     30 mg                                           1.75                                                0.50, 6.09                                           2.31         0.61, 8.67
     ≥45 mg                                          \_\_                                                \_\_                                                 \_\_         \_\_
  Persistent with Pioglitazone                                                                                                                                             
     Yes                                             2.35                                                0.79, 7.05                                           2.28         0.75, 6.96
     No                                              \_\_                                                \_\_                                                 \_\_         \_\_
  ACE Inhibitor Use                                                                                                                                                        
     Yes                                             0.84                                                0.26, 2.69                                           0.77         0.23, 2.50
     No                                              \_\_                                                \_\_                                                 \_\_         \_\_
  Beta Blocker Use                                                                                                                                                         
     Yes                                             1.01                                                0.40, 2.54                                           1.12         0.43, 2.90
     No                                              \_\_                                                \_\_                                                 \_\_         \_\_
  Calcium Channel Blocker Use                                                                                                                                              
     Yes                                             0.61                                                0.22, 1.67                                           0.58         0.21, 1.59
     No                                              \_\_                                                \_\_                                                 \_\_         \_\_
  Thiazide Use                                                                                                                                                             
     Yes                                             0.74                                                0.31, 1.74                                           0.71         0.30, 1.73
     No                                              \_\_                                                \_\_                                                 \_\_         \_\_
  Statin Antihyperlipidemic Use                                                                                                                                            
     Yes                                             0.91                                                0.32, 2.64                                           0.90         0.30, 2.67
     No                                              \_\_                                                \_\_                                                 \_\_         \_\_
  Non-Statin Antihyperlipidemic Use                                                                                                                                        
     Yes                                             2.82                                                0.98, 7.64                                           2.77         0.98, 7.66
     No                                              \_\_                                                \_\_                                                 \_\_         \_\_
  Chronic Disease Score                              1.05                                                0.86, 1.29                                           1.03         0.84, 1.26
  Neuropathy                                                                                                                                                               
     Yes                                             0.82                                                0.16, 4.24                                           0.90         0.16, 5.21
     No                                              \_\_                                                \_\_                                                 \_\_         \_\_
  Retinopathy                                                                                                                                                              
     Yes                                             1.43                                                0.19, 10.93                                          1.23         0.15, 10.20
     No                                              \_\_                                                \_\_                                                 \_\_         \_\_
  -------------------------------------------------- --------------------------------------------------- ---------------------------------------------------- ------------ -------------

1 -- c-statistic = 0.78

2 -- c-statistic = 0.80

DISCUSSION {#S9}
==========

This study provides additional information about the real-world effectiveness of pioglitazone use as adjunctive therapy to other oral antihyperglycemic agents. We found that adding pioglitazone to regimens of other oral antihyperglycemic medication(s) for patients with inadequate glycemic control resulted in clinically significant reductions in A1C but less than half of the patients achieved an A1C\<7% after 90 days of pioglitazone use at a stable dose.

Pioglitazone has a distinct mechanism of action that can provide additional glucose reduction when added to a sulfonylurea and/or metformin.[@B24] According to its package insert, reductions in A1C of 0.8 to 1.7 percentage points from baseline were obtained when pioglitazone was used in combination with a sulfonylurea or metformin for 24 weeks.[@B7] Other studies have revealed mean reductions in A1C of 0.8 to 1.9 percentage points with pioglitazone use.[@B8],[@B9],[@B10],[@B11],[@B12],[@B13] Specifically, we identified a comparable mean A1C reduction over a similar follow-up time to that reported by Riedel and colleagues (-1.2 percentage points) for patients receiving combination TZD-metformin.[@B13] Our observed reduction in A1C was also clinically significant given the results of the UKPDS, which reported that for every 1% reduction in A1C, the risk of developing microvascular complications decreases by approximately 35%.[@B1],[@B2]

We found that higher baseline A1C levels were associated with greater change in A1C. Our finding suggests that patients with higher baseline A1C measurements may experience improved glycemic control from the addition of pioglitazone. Conversely, patients with worse glycemic control at baseline were less likely to achieve a goal A1C of \<7%; which is the definitive target in diabetes management, more so than is the magnitude of A1C change. Riedel and colleagues similarly identified a higher baseline A1C as a predictor of not achieving A1C goal.[@B13] Based on this[@B13] and our results, adjunct therapy with pioglitazone appears to lack effectiveness in achieving glycemic control targets, particularly in patients with a baseline A1C\>8%. An additional caveat to consider is that triple oral therapy has not demonstrated cost-effectiveness compared to a regimen of insulin and metformin.[@B25]

We found that the greater number of days between the index date and follow-up A1C was associated with a less favorable response to pioglitazone. This suggests that the A1C-lowering ability of pioglitazone may degenerate over time. This is contrary to the results of a recent clinical trial where the antihyperglycemic effect of pioglitazone was sustained over 2 years when used in combination with other oral antihyperglycemic agents such as gliclazide (a sulfonylurea not available in the United States) or metformin.[@B26] Our results may have varied due to the difference in study settings (e.g., clinical trials incorporate techniques to enhance adherence) and patient populations (e.g., patients were excluded from clinical trials because they had other co-morbid conditions).

Several aspects of our investigation warrant comment. The retrospective nature of our evaluation and lack of a pioglitazone-naïve control group prevented us from assessing causality and regression to the mean; however, we feel that this information is the best available data to describe what occurs in a real-world population of patients with DM2. As this was a naturalistic investigation, we investigated patients started on pioglitazone therapy who received the usual course of care which included the use of other oral antihyperglycemic agents. However, since our findings mirrored those reported in other studies,[@B6],[@B8],[@B9],[@B10],[@B11],[@B12],[@B13] we hypothesize that incorporation of a control group in our investigation would have yielded similar results. Nevertheless, future studies of pioglitazone efficacy should include an adequate control group.

Our data are derived from a limited sample size, and this was attributable to the stringent inclusion criteria we employed to provide a more rigorous assessment of the independent role pioglitazone played in achievement of the outcomes. Such stringent criteria may potentially introduce selection bias (e.g., patients who failed to respond to pioglitazone therapy during the 90 days after initiation were not included) that limits the generalizability of our findings. Inclusion of patients who failed to respond to pioglitazone therapy likely would have provided additional information about the patient population that was prone to fail to achieve an A1C\<7% but likely would not have illuminated the patient population that was prone to achieve an A1C\<7%.

The suboptimal dosing of adjunct pioglitazone detected in this real-world examination exposes the need for additional reinforcement for prescribers to optimize therapy should they choose to add pioglitazone to existing oral therapy. Additionally, we included a limited amount of variables in the multivariate analysis. Potentially important factors not found in the integrated databases (e.g., race/ethnicity, nutritional assessment, socioeconomic status, health behaviors) may also be associated with clinically significant differences in A1C change and/or achievement of A1C goals.[@B12],[@B13] However, the reported adjusted R^2^ and c-statistics of our models suggest that a substantial proportion of the variance in A1C change and goal achievement was accounted for by our models.

CONCLUSIONS {#S10}
===========

In this retrospective, naturalistic, pre-to-post evaluation, we found that adjunct pioglitazone therapy was associated with a clinically significant reduction in A1C, particularly in patients with higher baseline A1C measurements, and also an increase in the proportion of patients achieving A1C\<7% in those patients with a lower baseline A1C. These findings provide real-world evidence that pioglitazone as adjunct therapy may be associated with improved glycemic control; however, they also suggest that patients requiring greater hyperglycemic control (as shown by higher baseline A1C levels) are less likely to reach treatment targets, thus casting doubt on the clinical utility of pioglitazone therapy in combination with other oral agents. Future naturalistic studies utilizing adequate control groups are needed to confirm the effectiveness of pioglitazone in A1C reduction and maintenance of glycemic goals.
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